The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risks
Open accessAbstract
Summary: Background Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used, but are not without risks. Aim To provide evidence‐based management recommendations to help clinicians determine optimal long‐term NSAID therapy and the need for gastroprotective strategies based on an assessment of both gastrointestinal (GI) and cardiovascular (CV) risks. Methods A multidisciplinary group of 21 voting participants revised and voted on the statements and the strength of evidence (assessed according to GRADE) at a consensus meeting. Results An algorithmic approach was developed to help manage patients who require long‐term NSAID therapy. The use of low‐dose acetylsalicylic acid in patients with high CV risk was assumed. For patients at low GI and CV risk, a traditional NSAID alone may be acceptable. For patients with low GI risk and high CV risk, full‐dose naproxen may have a lower potential for CV risk than other NSAIDs. In patients with high GI and low CV risk, a COX‐2 inhibitor plus a proton pump inhibitor (PPI) may offer the best GI safety profile. When both GI and CV risks are high and NSAID therapy is absolutely necessary, risk should be prioritized. If the primary concern is GI risk, a COX‐2 inhibitor plus a PPI is recommended; if CV risk, naproxen 500 mg b.d. plus a PPI would be preferred. NSAIDs should be used at the lowest effective dose for the shortest possible duration. Conclusion More large, long‐term trials that examine clinical outcomes of complicated and symptomatic upper and lower GI ulcers are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Barkun, A. N., Bardou, M., Kuipers, E. J., Sung, J., Hunt, R. H., Martel, M., Sinclair, P., & for the International Consensus Upper Gastrointestinal Bleeding Conference Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00009 · Cited by 1,163
Self-citationPrevention of NSAID-induced gastroduodenal ulcers
Rostom, A., Dube, C., Wells, G. A., Tugwell, P., Welch, V., Jolicoeur, E., McGowan, J., Lanas, A., Rushton, E., & Shukla, T. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002296 · Cited by 470
Self-citationfor the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469
Trifan, A., Stanciu, C., Girleanu, I., Stoica, O. C., Singeap, A. M., Maxim, R., Chiriac, S. A., Ciobica, A., & Boiculese, L. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i35.6500 · Cited by 286
Anglin, R., Yuan, Y., Moayyedi, P., Tse, F., Armstrong, D., & Leontiadis, G. I. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.82 · Cited by 234
Self-citation
Metadata
- Authors
- ROSTOM, A., MOAYYEDI, P., HUNT, R., & FOR THE CANADIAN ASSOCIATION OF GASTROENTEROLOGY CONSENSUS GROUP
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2009-01-30
- Volume
- 29
- Issue
- 5
- Pages
- 481-496
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1986727655
- Cited by
- 160
- References
- 3
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risks. https://app.cochat.ai/papers/10.1111/j.1365-2036.2008.03905.x
- The paper
- ROSTOM, A., MOAYYEDI, P., HUNT, R., & FOR THE CANADIAN ASSOCIATION OF GASTROENTEROLOGY CONSENSUS GROUP. (2009). Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2008.03905.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.